linagliptin and semaglutide Fasting postprandial kidney haemodynamic effects of empagliflozin and in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double‐blind trial Glucoregulatory Hormones | GLP-1/GIP Receptor

Their effectiveness improves with a healthy diet and exercise

If the math says 10 doses, prepare for 9 reliable ones

Several factors may contribute to dizziness in patients taking GLP-1 medications: Hypoglycaemia (low blood glucose) particularly when GLP-1 agonists are used alongside other glucose-lowering medications such as sulphonylureas or insulin Dehydration resulting from reduced fluid intake due to decreased appetite or from gastrointestinal side effects such as nausea, vomiting, or diarrhoea Orthostatic hypotension a drop in blood pressure upon standing, which may occur due to volume depletion or rapid weight loss Reduced caloric intake significant appetite suppression may lead to inadequate nutrition, potentially causing weakness and dizziness The frequency and severity of dizziness vary between individuals and specific GLP-1 products

If youre interested to learn more, we have a guide about GLP-1 receptor agonists